Cargando…
Cancer Immunology and Immunotherapy
The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that us...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2011.
|
| Edición: | 1st ed. 2011. |
| Colección: | Current Topics in Microbiology and Immunology,
344 |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-14136-2 | ||
| 003 | DE-He213 | ||
| 005 | 20220111134813.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 110411s2011 gw | s |||| 0|eng d | ||
| 020 | |a 9783642141362 |9 978-3-642-14136-2 | ||
| 024 | 7 | |a 10.1007/978-3-642-14136-2 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Cancer Immunology and Immunotherapy |h [electronic resource] / |c edited by Glenn Dranoff. |
| 250 | |a 1st ed. 2011. | ||
| 264 | 1 | |a Berlin, Heidelberg : |b Springer Berlin Heidelberg : |b Imprint: Springer, |c 2011. | |
| 300 | |a XIV, 306 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Current Topics in Microbiology and Immunology, |x 2196-9965 ; |v 344 | |
| 520 | |a The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "first-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Immunology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Immunology. |
| 700 | 1 | |a Dranoff, Glenn. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783642267888 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642141355 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642141379 |
| 830 | 0 | |a Current Topics in Microbiology and Immunology, |x 2196-9965 ; |v 344 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-642-14136-2 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||